Table 1.
Guidelines for selecting those patients who may get optimal benefit from autologous stem cell transplantation
| Patient | AML | Cytogenetics (MRC) | ELNa | Status | CR | Consolidation | MRD | Pre-transplant regimen | Maintenance |
|---|---|---|---|---|---|---|---|---|---|
| Up to 75 years and fit | All but M3 | Good or Intermediate | Favourable or Intermediate | CR1 | Rapid remitterb | At least 2 HD ARA-C courses prior to LK | Negativec | BUMEL or BUCY or CY FTBI | AZA + Venetoclax |
| All three | |||||||||
| FLT3 unmutated | Marrow PB | AZA | |||||||
| LK | CAR-T cells | ||||||||
| M3 | CR2 | Negative | Same |
a
ELN: European Leukemia Network prognostic classification 2010.
b
Rapid remitter: reaching complete remission with only one induction chemotherapy course.
c
No detectable residual disease by either flow cytometry and/or molecular biology.
MRD, Minimal residual disease; MRC, UK Medical research council; HD ARA-C, High dose Cytosine-arabinoside; AZA, 5 Azacytidine.